CA3165422A1 - Methodes de traitement de troubles cerebraux - Google Patents

Methodes de traitement de troubles cerebraux

Info

Publication number
CA3165422A1
CA3165422A1 CA3165422A CA3165422A CA3165422A1 CA 3165422 A1 CA3165422 A1 CA 3165422A1 CA 3165422 A CA3165422 A CA 3165422A CA 3165422 A CA3165422 A CA 3165422A CA 3165422 A1 CA3165422 A1 CA 3165422A1
Authority
CA
Canada
Prior art keywords
nac
brain
congener
subject
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3165422A
Other languages
English (en)
Inventor
Douglas A. GREENE
Rajiv R. Ratan
Thomas I. Bradshaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Burke Neurological Institute
Neuronasal Inc
Original Assignee
Burke Neurological Institute
Neuronasal Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Burke Neurological Institute, Neuronasal Inc filed Critical Burke Neurological Institute
Publication of CA3165422A1 publication Critical patent/CA3165422A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des méthodes d'administration de N-acétylcystéine (NAC) par administration intranasale du nez vers le cerveau. L'effet de l'administration intranasale du nez vers le cerveau de NAC peut être surveillé à l'aide d'une technique analytique, par exemple, la spectroscopie par résonance magnétique (SRM). Dans certains modes de réalisation, l'administration intranasale du nez vers le cerveau de NAC peut être utilisée pour traiter une affection, par exemple, une lésion cérébrale.
CA3165422A 2019-12-18 2020-12-18 Methodes de traitement de troubles cerebraux Pending CA3165422A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962949640P 2019-12-18 2019-12-18
US62/949,640 2019-12-18
US202062970254P 2020-02-05 2020-02-05
US62/970,254 2020-02-05
PCT/US2020/066179 WO2021127541A1 (fr) 2019-12-18 2020-12-18 Méthodes de traitement de troubles cérébraux

Publications (1)

Publication Number Publication Date
CA3165422A1 true CA3165422A1 (fr) 2021-06-24

Family

ID=76437600

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3165422A Pending CA3165422A1 (fr) 2019-12-18 2020-12-18 Methodes de traitement de troubles cerebraux

Country Status (7)

Country Link
US (1) US20210186911A1 (fr)
EP (1) EP4076425A1 (fr)
JP (1) JP2023518635A (fr)
CN (1) CN115484945A (fr)
AU (1) AU2020407239A1 (fr)
CA (1) CA3165422A1 (fr)
WO (1) WO2021127541A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022067232A1 (fr) * 2020-09-28 2022-03-31 Commercial Automation, Llc Kiosque de stockage et de vente de produits alimentaires
EP4221645A1 (fr) * 2020-10-01 2023-08-09 Lyra Therapeutics, Inc. Implants osmotiques de distribution de médicaments
WO2023150392A1 (fr) * 2022-02-07 2023-08-10 Neuronasal, Inc. Administration intranasale de n-acétylcystéine et ses utilisations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007143040A (ru) * 2005-04-21 2009-05-27 Гленн А. ГОЛДШТЕЙН (US) Амид n-ацетилцистеина (амид nac) в лечении заболеваний и состояний, связанных с окислительным стрессом
EP2749552B1 (fr) * 2007-04-17 2015-11-18 Codman & Shurtleff, Inc. Hybrides curcumine-resvératrol
JP7074663B6 (ja) * 2015-05-28 2022-08-01 ベイラー カレッジ オブ メディスン グルタチオンレベルを改善するためのｎ－アセチルシステイン及びグリシンの補給の効果
EP3618824A4 (fr) * 2017-05-02 2021-06-23 Neuronasal, LLC Utilisation de n-acétylcystéine pour traiter des troubles du système nerveux central
EP3700525A4 (fr) * 2017-10-27 2021-08-25 Beyond Barriers Therapeutics, Inc. Administration améliorée d'antioxydants pour le traitement de troubles du système nerveux central impliquant un stress oxydatif

Also Published As

Publication number Publication date
WO2021127541A1 (fr) 2021-06-24
JP2023518635A (ja) 2023-05-08
AU2020407239A1 (en) 2022-07-28
CN115484945A (zh) 2022-12-16
EP4076425A1 (fr) 2022-10-26
US20210186911A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
US20210186911A1 (en) Methods of treating brain disorders
US7855176B1 (en) Reduced volume formulation of glatiramer acetate and methods of administration
US20230321020A1 (en) Magnetic resonance spectroscopy to calibrate and select doses, formulations, and devices for intra-nasal administration of n-acetylcysteine
US8920373B2 (en) Reduced volume formulation of glatiramer acetate and methods of administration
CN110461319A (zh) 治疗癫痫发作紊乱和prader-willi综合征的方法
US20240024267A1 (en) Methods of administering glutathione precursors
Tanne et al. Severe tramadol overdoses in children: a case series admitted to paediatric intensive care unit
Herold Lamotrigine as a possible cause of QRS prolongation in a patient with known seizure disorder
US20190314297A1 (en) Combination therapy of cbd and copaxone
Algahtani et al. Lacosamide-induced excessive laughing in a patient with Lennox–Gastaut syndrome
TW202131910A (zh) 使用mtorc1調節劑的治療方法
Maroney et al. Anti-epileptic medications
WO2023150392A1 (fr) Administration intranasale de n-acétylcystéine et ses utilisations
CN114828960A (zh) 治疗儿童个体的cln2病的方法
WO2023099013A1 (fr) Procédés de traitement de patients atteints d'une lésion cérébrale et procédés d'augmentation de la valeur de l'échelle de résultats de glasgow étendue de patients atteints d'une lésion cérébrale
Al-Mufti et al. Status 15
Ivaturi Intranasal and rectal diazepam for rescue therapy: Assessment of pharmacokinetics and tolerability
Mistry et al. Neuromuscular Respiratory Failure
Al-Mufti et al. Status Epilepticus in the Neurocritical Care Unit
Mirski et al. The subspecialty of neurologic critical care has come of age. In years past, neuro
Lemkuil et al. Neurointensive care
Aprile et al. Multinevritis of cranial nerves following inhalation of toxins